Wild-type (senile) amyloidosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Wild-type (senile) amyloidosis}}
{{Wild-type (senile) amyloidosis}}
{{CMG}}
{{CMG}}{{AE}}{{Sab}}


==Overview==
==Overview==
Wild-type (senile) amyloidosis, as the name suggests, is a [[disease]] of the [[Old age|elderly]]. The clinical picture of the [[disease]] corresponds to the type of [[Organ (anatomy)|organ]] or organ system involved. It most commonly affects the [[heart]] and hence, clinical features pertaining to [[Heart|cardiac]] pathologies, dominate the clinical course of the [[disease]]. If left untreated, wild-type (senile) amyloidosis can lead to [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]] and eventually death. Wild-type (senile) amyloidosis is most commonly complicated by [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]]. The [[median]] duration of survival after [[diagnosis]] is 75 months.


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
Line 9: Line 10:


* In [[amyloidosis]], insoluble fibrils of [[amyloid]] are deposited in the [[Organ (anatomy)|organs]], causing organ dysfunction and eventually death.<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref>
* In [[amyloidosis]], insoluble fibrils of [[amyloid]] are deposited in the [[Organ (anatomy)|organs]], causing organ dysfunction and eventually death.<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref>
*Wild-type (senile) amyloidosis, as the name suggests, is a disease of the elderly.
*Wild-type (senile) amyloidosis, as the name suggests, is a [[disease]] of the [[Old age|elderly]].
*The clinical picture of the disease corresponds to the type of organ or organ system involved.
*The clinical picture of the [[disease]] corresponds to the type of [[Organ (anatomy)|organ]] or organ system involved.
*It most commonly affects the heart and hence, clinical features pertaining to cardiac pathologies, dominate the clinical course of the disease.
*It most commonly affects the [[heart]] and hence, clinical features pertaining to [[Heart|cardiac]] pathologies, dominate the clinical course of the [[disease]].
*The deposition of transthyretin (TTR) in the heart causes it to start functionally failing.
*The deposition of [[Transthyretin|transthyretin (TTR)]] in the [[heart]] causes it to start [[Heart failure|functionally failing]].<ref>{{Cite journal
*The constellation of signs and symptoms of a TTR affected heart can mimic heart failure due to old age and can thus mask wild-type (senile) amyloidosis.
| author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]]
| title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis
| journal = [[Archives of internal medicine]]
| volume = 165
| issue = 12
| pages = 1425–1429
| year = 2005
| month = June
| doi = 10.1001/archinte.165.12.1425
| pmid = 15983293
}}</ref>
*The constellation of [[Medical sign|signs]] and [[Symptom|symptoms]] of a [[Transthyretin|TTR]] affected [[heart]] can mimic [[heart failure]] due to [[old age]], and can thus mask the systemic involvement of wild-type (senile) amyloidosis.
*If left untreated, wild-type (senile) amyloidosis can lead to [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]] and eventually death.<ref name=":0">{{Cite journal
| author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]]
| title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis
| journal = [[Archives of internal medicine]]
| volume = 165
| issue = 12
| pages = 1425–1429
| year = 2005
| month = June
| doi = 10.1001/archinte.165.12.1425
| pmid = 15983293
}}</ref>
*
*


===Complications===
===Complications===
* Wild-type (senile) amyloidosis is most commonly complicated by [[Heart failure with reduced ejection fraction|heart failure with reduced ejection fraction (HFrEF)]].<ref name=":0" />
* Other [[Complication (medicine)|complications]] include:
**[[Left bundle branch block|Left bundle branch block (LBBB)]]<ref>{{Cite journal
| author = [[Claudio Rapezzi]], [[Giampaolo Merlini]], [[Candida C. Quarta]], [[Letizia Riva]], [[Simone Longhi]], [[Ornella Leone]], [[Fabrizio Salvi]], [[Paolo Ciliberti]], [[Francesca Pastorelli]], [[Elena Biagini]], [[Fabio Coccolo]], [[Robin M. T. Cooke]], [[Letizia Bacchi-Reggiani]], [[Diego Sangiorgi]], [[Alessandra Ferlini]], [[Michele Cavo]], [[Elena Zamagni]], [[Maria Luisa Fonte]], [[Giovanni Palladini]], [[Francesco Salinaro]], [[Francesco Musca]], [[Laura Obici]], [[Angelo Branzi]] & [[Stefano Perlini]]
| title = Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types
| journal = [[Circulation]]
| volume = 120
| issue = 13
| pages = 1203–1212
| year = 2009
| month = September
| doi = 10.1161/CIRCULATIONAHA.108.843334
| pmid = 19752327
}}</ref>
** [[Peripheral neuropathy]]
** [[Tendon]] [[rupture]]


===Prognosis===
===Prognosis===
*In comparison with [[Primary amyloidosis|AL amyloidosis]], the severity of [[heart failure]] in wild-type (senile) amyloidosis is less.<ref>{{Cite journal
| author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]]
| title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis
| journal = [[Archives of internal medicine]]
| volume = 165
| issue = 12
| pages = 1425–1429
| year = 2005
| month = June
| doi = 10.1001/archinte.165.12.1425
| pmid = 15983293
}}</ref>
*The [[median]] duration of survival after [[diagnosis]] is 75 months.<ref>{{Cite journal
| author = [[Belinda Ng]], [[Lawreen H. Connors]], [[Ravin Davidoff]], [[Martha Skinner]] & [[Rodney H. Falk]]
| title = Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis
| journal = [[Archives of internal medicine]]
| volume = 165
| issue = 12
| pages = 1425–1429
| year = 2005
| month = June
| doi = 10.1001/archinte.165.12.1425
| pmid = 15983293
}}</ref>


==References==
==References==

Latest revision as of 19:24, 17 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis natural history, complications and prognosis

CDC on Wild-type (senile) amyloidosis natural history, complications and prognosis

Wild-type (senile) amyloidosis natural history, complications and prognosis in the news

Blogs on Wild-type (senile) amyloidosis natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

Wild-type (senile) amyloidosis, as the name suggests, is a disease of the elderly. The clinical picture of the disease corresponds to the type of organ or organ system involved. It most commonly affects the heart and hence, clinical features pertaining to cardiac pathologies, dominate the clinical course of the disease. If left untreated, wild-type (senile) amyloidosis can lead to heart failure with reduced ejection fraction (HFrEF) and eventually death. Wild-type (senile) amyloidosis is most commonly complicated by heart failure with reduced ejection fraction (HFrEF). The median duration of survival after diagnosis is 75 months.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
  2. ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)
  3. ↑ 3.0 3.1 Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)
  4. ↑ Claudio Rapezzi, Giampaolo Merlini, Candida C. Quarta, Letizia Riva, Simone Longhi, Ornella Leone, Fabrizio Salvi, Paolo Ciliberti, Francesca Pastorelli, Elena Biagini, Fabio Coccolo, Robin M. T. Cooke, Letizia Bacchi-Reggiani, Diego Sangiorgi, Alessandra Ferlini, Michele Cavo, Elena Zamagni, Maria Luisa Fonte, Giovanni Palladini, Francesco Salinaro, Francesco Musca, Laura Obici, Angelo Branzi & Stefano Perlini (2009). "Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types". Circulation. 120 (13): 1203–1212. doi:10.1161/CIRCULATIONAHA.108.843334. PMID 19752327. Unknown parameter |month= ignored (help)
  5. ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)
  6. ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Wild-type_(senile)_amyloidosis_natural_history,_complications_and_prognosis&oldid=1592021"